Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety-Reference-Cited by-同舟云学术

Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety

Published:2019-03 Issue:3 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ritchie Brianne M.¹,Barreto Jason N.¹,Barreto Erin F.¹²,Crow Stacy A.¹,Dierkhising Ross A.³,Jannetto Paul J.⁴,Tosh Pritish K.⁵,Razonable Raymund R.⁵⁶

Affiliation:

1. Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA

2. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA

3. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA

4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

5. Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

6. William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA

Abstract

The clinical utility of ganciclovir therapeutic drug monitoring (TDM) is unknown. We retrospectively analyzed adult patients treated for cytomegalovirus (CMV) infection with ganciclovir with TDM between 2005 and 2015.

Funder

Mayo Midwest Pharmacy Research Committee

Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01855-18

Reference53 articles.

1. Infection in Solid-Organ Transplant Recipients

2. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant

3. Not the Usual Viral Suspects: Parvovirus B19, West Nile Virus, and Human T-Cell Lymphotrophic Virus Infections After Kidney Transplantation

4. Management Strategies for Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients

5. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus in haematopoietic cell transplantation - The troll is still there;Best Practice & Research Clinical Haematology;2024-09

2. Nephrotoxicity of Intravenous Ganciclovir in Pediatric Hematopoietic Cell Transplant Recipients;Pediatric Infectious Disease Journal;2024-07-23

3. Effects of ganciclovir combined with recombinant human interferon-α on clinical efficacy and immune function in children with infectious mononucleosis;Pakistan Journal of Medical Sciences;2024-06-20

4. Therapeutic Myths in Solid Organ Transplantation Infectious Diseases;Open Forum Infectious Diseases;2024-06-15

5. A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient;Journal of Pharmaceutical Health Care and Sciences;2024-06-07